Genentech reports Phase III data for Hemlibra without inhibitors

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported full data from the Phase III HAVEN 3 trial of Hemlibra emicizumab-kxwh as prophylaxis in hemophilia A patients without Factor VIII inhibitors. Data were presented at the World Federation of Hemophilia meeting in Glasgow.

Hemlibra is approved in the U.S., Europe and Japan

Read the full 515 word article

User Sign In